Overview

Study to Assess the Safety and Effectiveness of NMRA-335140-501

Status:
Recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
This is a 52-week open-label extension (OLE) study that will evaluate the safety, tolerability, and effectiveness of NMRA-335140 in participants with major depressive disorder (MDD). Participants who completed a parent study investigating the efficacy of NMRA-335140 as a treatment for MDD (ie, NMRA-335140-301, NMRA-335140-302, or NMRA-335140-303), who provide informed consent, and who have no evidence of safety concerns that would preclude treatment with NMRA-335140 may be enrolled into this extension study.
Phase:
Phase 3
Details
Lead Sponsor:
Neumora Therapeutics, Inc.